BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27554841)

  • 41. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.
    Tran T; Jones CL; Williamson SR; Eble JN; Grignon DJ; Zhang S; Wang M; Baldridge LA; Wang L; Montironi R; Scarpelli M; Tan PH; Simper NB; Comperat E; Cheng L
    Histopathology; 2016 May; 68(6):850-7. PubMed ID: 26310887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.
    Wang J; Shen Q; Shi Q; Yu B; Wang X; Cheng K; Lu G; Zhou X
    J Exp Clin Cancer Res; 2014 Dec; 33(1):109. PubMed ID: 25527865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adult renal cell carcinoma with rhabdoid differentiation: incidence and clinicopathologic features in Chinese patients.
    Yang X; Xi C; Jin J; Zhou L; Su J; Liu L; Liu Y
    Ann Diagn Pathol; 2015 Apr; 19(2):57-63. PubMed ID: 25708024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances of immunohistochemistry for diagnosis of renal tumors.
    Kuroda N; Tanaka A; Ohe C; Nagashima Y
    Pathol Int; 2013 Aug; 63(8):381-90. PubMed ID: 23957913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Xp11 translocation renal cell carcinoma morphologically mimicking clear cell-papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas.
    Parihar A; Tickoo SK; Kumar S; Arora VK
    Int J Surg Pathol; 2015 May; 23(3):234-7. PubMed ID: 25519951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
    Fuehrer NE; Keeney GL; Ketterling RP; Knudson RA; Bell DA
    Arch Pathol Lab Med; 2012 Jun; 136(6):623-6. PubMed ID: 22646268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
    Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
    Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
    Selinger C; Cooper W; Lum T; McNeil C; Morey A; Waring P; Amanuel B; Millward M; Peverall J; Van Vliet C; Christie M; Tran Y; Diakos C; Pavlakis N; Gill AJ; O'Toole S
    Histopathology; 2015 Nov; 67(5):654-63. PubMed ID: 25847523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
    Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
    J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased ALK1 copy number and renal cell carcinoma-a case report.
    Ryan C; Mayer N; Cunningham J; Hislop G; Pratt N; Fleming S
    Virchows Arch; 2014 Feb; 464(2):241-5. PubMed ID: 24318419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
    Williamson SR; Gupta NS; Eble JN; Rogers CG; Michalowski S; Zhang S; Wang M; Grignon DJ; Cheng L
    Am J Surg Pathol; 2015 Nov; 39(11):1502-10. PubMed ID: 26457355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.
    Sukov WR; Ketterling RP; Lager DJ; Carlson AW; Sinnwell JP; Chow GK; Jenkins RB; Cheville JC
    Hum Pathol; 2009 Sep; 40(9):1296-303. PubMed ID: 19386349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
    Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
    Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.